TG Therapeutics recently initiated an open-label Phase 2 trial of BRIUMVI (ublituximab-xiiy) in about 60 adults with ...

The collaboration will bring Cortechs.ai's quantitative MRI analysis into Viz.ai's care coordination platform, beginning with ...

Earlier diagnostic options for MS are now possible, Zyn nicotine pouches get an FDA risk claim, and norovirus concerns rise.

According to the latest market analysis by Future Market Insights, the global B-Cell Depletion Therapy Market is projected to ...

Our latest CPD module explores five common but challenging neurology cases encountered in general practice, and discusses evidence-based approaches to assessment, investigation and management.

True disruption demands both vision and courage, and these ten remarkable women are leading that charge in 2026.

Today at ISSCR 2026, new preliminary clinical data was presented evaluating an induced pluripotent stem cell (iPSC)-derived ...

I was diagnosed with relapsing-remitting multiple sclerosis (RRMS) at the age of 46.

Scientists find immune markers that may catch Lyme disease earlier and explain why some patients' symptoms linger.

A new study describes a gene therapy strategy that uses the brain's own glymphatic transport system to distribute engineered viral vectors throughout the brain.